Vol. 13, Issue 7 (2024)

Levamisole (LEVA) and cyclophosphamide (CYP) are two of the most popular Immunomodulatory medications used to treat several serious diseases. However, these Immunomodulatory has been proven to increase vulnerability to type 1 diabetes mellitus. The purpose of the present study was to investigate the incidence of hyperglycemia during immunotherapy with cyclophosphamide and levamisole, and the possible benefit of providing plant extracts of Berberis lycium Royle and Withania somnifera as hypoglycemic agents. CYP and Levamisole were introduced in rats along with root extract of Berberis lycium Royle (BLR), and Withania somnifera (WS) to evaluate the average glucose level in rats and the HbA1c level was measured after 28 days. The result of the study showed a significant (p<0.05) increase in percent HbA1c level in the CYP group, LEVA group, and at its highest level in the CYP+LEVA group of rats compared to the groups treated with plant extracts. The HbA1c levels was found to be at the control level or non-diabetic range in the groups treated with plant extract. It was suggested that CYP and LEVA may have had an impact on glycemic control in the rats receiving immunotherapy therefore, patients with diabetes who are receiving cyclophosphamide immunotherapy may benefit from the combination of the two plant extracts.